Literature DB >> 1742221

The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party.

R C Leonard1, R L Hayward, R J Prescott, J X Wang.   

Abstract

A prognostic model was developed by examination of the prospectively recorded presentation characteristics of patients presenting with low grade non-Hodgkin's lymphomas (LGL). A geographically distinct group (Edinburgh and Borders) was excluded in order to test the validity of the model based on the rest of the Scotland and Newcastle Lymphoma Group (SNLG) population. Between 1979 and 1987 506 patients presented with low grade lymphoma according to Working Formulation definition within one of each of the three main pathology categories. The median available follow-up was 47 months. In a multivariate analysis performance status, age, stage, gender and haemoglobin all contributed separately. 25% of all patients had relatively good prognosis with a median survival not reached and 84% alive at 5 years. Conversely for the worst prognostic group of 25% of patients the median survival is 18 months with only 26% surviving at 5 years. Finally for the intermediate group of 50% of all patients, median survival is 69 months with 58% alive at 5 years. These striking prognostic separations are shown also to be valid in sub-group analysis. Thus young patients within any pathology subgroup have been identified with bad prognostic lymphoma for whom novel strategies in therapy should be devised.

Entities:  

Mesh:

Year:  1991        PMID: 1742221     DOI: 10.1093/oxfordjournals.annonc.a058044

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  8 in total

Review 1.  Management of non-Hodgkin's lymphomas.

Authors:  P J Mounter; A L Lennard
Journal:  Postgrad Med J       Date:  1999-01       Impact factor: 2.401

Review 2.  Clinical and molecular prognostic factors in follicular lymphoma.

Authors:  Andrew J Davies
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

Review 3.  Low-grade lymphomas: new entities and treatment concepts.

Authors:  F B Hagemeister
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

4.  Prognostic significance of biochemical markers in African Burkitt's lymphoma.

Authors:  F K N Arthur; L Owusu; F A Yeboah; T Rettig; A Osei-Akoto
Journal:  Clin Transl Oncol       Date:  2011-10       Impact factor: 3.405

5.  Assessment of prognostic factors in follicular lymphoma patients.

Authors:  E Kondo; M Ogura; Y Kagami; H Taji; K Miura; T Takeuchi; S Maeda; S Asakura; R Suzuki; S Nakamura; Y Morishima
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

6.  A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma.

Authors:  S M Kelsey; A C Newland; G V Hudson; A M Jelliffe
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

7.  A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.

Authors:  A Rohatiner; J Radford; D Deakin; H Earl; S B Love; O Price; A Wilson; T A Lister
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

8.  Radiotherapy as an effective treatment modality for follicular lymphoma: a single institution experience.

Authors:  Seo Hee Choi; Jaeho Cho; Jin Seok Kim; June-Won Cheong; Chang-Ok Suh
Journal:  Radiat Oncol J       Date:  2015-12-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.